Appendix Table C53Trial description: oral selective antihistamine plus intranasal corticosteroid versus intranasal corticosteroid

Author, YearLocation, Site(s)Enrollment/Treatment DurationFunding/Author Industry DisclosuresNInclusion CriteriaExclusion CriteriaaRescue Medication UseObjective DiagnosisRun in PeriodPollen CountPatient BlindingAssessor Blinding
Anolik, 2008N.America
Multiple
March 1995
2.1 weeks
NR
Industry
345Minimum SAR severity and durationChronic asthma
Immunotherapy
Infection
Deformities
No
Barnes, 2006Europe
Single
June 2004
2 weeks
Academia
Industry
62SAR meds/-
Pregnancy
Deformities
Yes
Benincasa, 1994Europe
Multiple
May 1990
8 weeks
Industry
Industry
454Minimum SAR severity and durationSAR meds/+
Other meds
Pregnancy
Infection
Deformities
Yes
Di Lorenzo, 2004Europe
Multiple
April 2001
6 weeks
Health systemb
NR
40Minimum SAR severity and durationSAR meds/+
Chronic asthma
Pregnancy
Infection
Deformities
Yes
Ratner, 1998N.America
Multiple
2 weeksIndustry
Industry
300Minimum SAR severity and durationSAR meds/+
Pregnancy
Infection
Deformities
No

N = Patients randomized to comparator groups of interest; NR = not reported; SAR = seasonal allergic rhinitis.

a

+, -, or NR indicates whether FDA-recommended washout periods were required (+), were not required (-), or were not reported (NR) for restricted SAR medications prior to trial entry.

b

Ministero Italiano Universita` e Ricerca (MIUR).

From: Appendix C, Evidence Tables

Cover of Treatments for Seasonal Allergic Rhinitis
Treatments for Seasonal Allergic Rhinitis [Internet].
Comparative Effectiveness Reviews, No. 120.
Glacy J, Putnam K, Godfrey S, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.